Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tyrosine kinase 2 short hairpin RNA
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
Tyrosine kinase 2 (TYK2) short hairpin RNA (shRNA) is an experimental RNA interference (RNAi) agent designed to silence the expression of the TYK2 gene. In the context of oncology research, specifically breast cancer, TYK2 has been identified as a mechanosensitive metastasis suppressor that preserves epithelial integrity under low extracellular matrix (ECM) stiffness. Depletion of TYK2 via shRNA leads to the nuclear translocation of the transcription factor TWIST1, triggering epithelial-mesenchymal transition (EMT) and multicellular invasion. While TYK2 inhibitors like deucravacitinib are used clinically for autoimmune diseases, experimental use of TYK2 shRNA in triple-negative breast cancer (TNBC) models has demonstrated that loss of TYK2 promotes local invasion and lung metastasis without affecting primary tumor growth. This suggests that TYK2 serves as a fundamental stiffness-governed epithelial defense mechanism.
- Other names
- tyrosine kinase 2 short hairpin RNATYK2 short hairpin RNATYK-2 short hairpin RNATYK 2 short hairpin RNA
02
Targets
TYK2 (Tyrosine kinase 2)
Beyond the preview
Go deeper on tyrosine kinase 2 short hairpin RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tyrosine kinase 2 short hairpin RNA.